# Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.

> **NCT06905288** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 70 (estimated)

## Conditions studied

- Ankylosing Spondylitis

## Interventions

- **DRUG:** Secukinumab

## Key facts

- **NCT ID:** NCT06905288
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-02
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06905288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06905288, "Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06905288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*